手助腹腔镜肝癌切除23例

目的探讨手助腹腔镜肝癌切除的可行性和安全性。方法对病变位于肝脏外周部位(Ⅱ~Ⅵ段)的23例病人,肝细胞癌20例,肝内胆管细胞癌2例,肝囊腺癌1例。采用手助腹腔镜行肝切除术。结果23例手助腹腔镜肝切除均获得成功,规则性肝叶(段)切除17例,肝不规则切除6例,平均手术时间为105 m in,平均出血量187 m l,术后无严重并发症发生,术后平均住院日为9.5 d。结论手助腹腔镜肝切除是安全可行的,缩短手术时间,减少出血的微创手术方式。     

电镜下的乙型肝炎表面抗原

本文对81例乙型肝炎病人的肝活检组织进行了电镜观察,发现HBsAg的阳性率达93.8％。电镜下,HBsAg细丝不仅有一般的管状细丝型,还有分枝管型和管泡型,而且CAH病人肝组织不易找到HBsAg丝(易见者仅9％),CPH,CLH则多数(79.5％)为易见及可见,二者有高度显著性差异(P<0.01)。     

彩超对肾移植术后并发肝脏恶性肿瘤的监测

目的　探讨彩超在肾移植术后并发肝脏恶性肿瘤监测中的应用价值。　方法　应用 Acuson12 8XP彩色多普勒超声诊断仪 ,对在我院行异体肾移植手术的终末期尿毒症患者 12 0 0例进行规律随访。　结果　发现 17例恶性肿瘤 ,其中肝癌 7例 ,占 4 1.17%。 5例肿块单发 ,2例多发 ;肿块最大 10 cm× 10 cm,最小 2 .3cm× 2 .1cm。其中 6例手术病理证实 ,1例肝活检证实。　结论　对移植肾术后患者 ,首选彩超随访肝脏变化 ,能早期发现肿瘤 ,为临床选择治疗方案提供时机 ,并提高换肾后发生恶性肿瘤患者的存活率     

无创伤性测定门静脉压力与肝血流二法联合应用研究肝硬化的价值

目的　为临床研究肝硬化提供有价值的手段。方法　采用99mTc -RBC测定 93例肝硬化患者肝血流 ,选择峰时 (Tmax) ,半廓清时 (T1/2 )、廓清率 (K值 )、肝血流 (LBF)等作为观察指标 ,与正常对照组比较 ;同时用99mTc-MIBI经直肠给药测定其中 5 4例患者门静脉压力 (PVP) ,以心 /肝 (H/L)比值作为分流指数。结果　肝硬化组Tmax、T1/2 、K及LBF分别为 1.2 6± 0 .99(93)min、5 .75± 3.38(93)min、0 .15 4± 0 .116 (93)及 0 .6 10± 0 .2 89(93)L/min ,除Tmax外 ,与对照组均有非常显著性差异 ;Child -A、B、C级各组之间 (除Tmax外 )也均有非常显著性差异或显著性差异 ;Child -A、B、C级各组H/L分别为 0 .49± 0 .18(2 1)、0 .6 9± 0 .16 (15 )、0 .91± 0 .2 1(18) ;PVP分别为 2 .2 2± 0 .5 7(2 1)kPa、2 .85± 0 .38(15 )kPa及 3.5 4± 0 .6 5 (18)kPa。而对照组的H/L及PVP分别为 0 .30± 0 .12 (16 )及 1.6 1± 0 .38(16 )kPa。Child -A、B、C级各组分别与对照组及各组之间比较 ,除Child -B与C级组PVP无显著性差异 (P >0 .0 5 )外 ,其余均有非常显著性差异 (P <0 .0 1)及显著性差异 (P <0 .0 5 )。结论　本法测定肝血流及门脉压力方便 ,无创伤 ,对分析病情 ,判断疗效 ,指导制订治疗方案 ,估计预后等均有较     

螺旋CT三期扫描对肝纤维化诊断价值研究

目的探讨螺旋CT三期扫描对肝纤维化的诊断价值。方法对66例经肝穿刺活检病理证实的慢性乙型肝炎肝纤维化患者组和42例正常对照组进行螺旋CT三期增强扫描。根据纤维化程度分期进行影像资料和相关指标的统计分析。结果肝左叶增大,肝表面形态及肝实质密度的改变,脾脏增大,门静脉增宽和侧枝循环的建立等影像学改变,随着肝纤维化严重程度的加重而有统计学差异。本研究显示57例肝纤维化患者螺旋CT三期扫描诊断肝纤维化52例,敏感性91.2%,特异性77.8%。各期肝纤维化分期准确28例,准确率49.1%;准确判断轻度纤维化(S1、S2)或重度纤维化(S3、S4)44例,准确率77.2%,诊断早期肝硬化16例,准确率84.2%。结论螺旋CT三期扫描能判断肝纤维化的程度,而且是动态观察肝纤维化的病程演进和临床随访的有效手段。     

Hepatic Disposition Characteristics of Electrically Charged Macromolecules in Rat in Vivo and in the Perfused Liver

The effect of electric charge on the hepatic disposition of macromolecules was studied in the rat. Charged derivatives of dextran (T-70) and bovine serum albumin (BSA), mitomycin C–dextran conjugates (MMC-D), and lactosaminated BSA (Lac-BSA) were employed as model macromolecules. After intravenous injection, cationic macromolecules were rapidly eliminated from plasma because of their extensive hepatic uptake, while anionic and neutral macromolecules were slowly eliminated. Cationic macromolecules were recovered from parenchymal and nonparenchymal hepatic cells at a cellular uptake (per unit cell number) ratio of 1.4–3.2, while that of Lac-BSA was 14. During liver perfusion using a single-pass constant infusion mode, cationic macromolecules were continuously extracted by the liver, with extraction ratios at steady-state (E _ss) ranging between 0.03 and 0.54, whereas anionic and neutral macromolecules were almost completely recovered in the outflow at steady state. The E _ss for cationized BSA (Cat-BSA) and cationic MMC-Dcat were concentration dependent and decreased at low temperatures and in the presence of colchicine and cytochalasin B. The possible participation of the internalization process in the uptake of cationic macromolecules by hepatocytes was suggested.     

丹参酚酸B盐对内皮素诱导的人肝星状细胞收缩的抑制作用及机制研究

目的 以培养的人肝星状细胞（HSC）为研究对象，观察内皮素-1（ET-1）对HSC的收缩作用及丹参酚酸B盐（SA-B）对ET-1的抑制作用，并探讨SA B抑制HSC收缩的作用环节和可能作用机制。 方法 采用酶消化、Nycodenz密度梯度离心的方法分离人HSC，以胶原凝胶收缩法观察ET-1对于传代HSC的收缩作用，以及低、中、高3种剂量的SA B对其不同的干预作用；将ET-1、SA-B直接添加于传代HSC的无血清培养液中，以激光共聚焦显微镜技术观测HSC内钙离子浓度的变化。 结果 胶原凝胶收缩实验显示，ET-1可诱导HSC收缩（P<0.01）；3种剂量的SA-B可明显抑制ET-1诱导的HSC收缩（均P<0.01）；加入ET-1后，HSC形态学改变明显，细胞数量减少，但SA B对这些改变也有抑制。激光共聚焦显微镜下观察，ET-1可刺激细胞内钙离子短暂迅速增加，加入SA-B后，该作用被明显抑制。 结论 SA-B能显著抑制ET-1诱导的HSC收缩，其抑制收缩的机制与降低HSC内的钙离子浓度有关。SA-B的抑制HSC收缩作用可能是其抗肝纤维化及门脉高压的机制之一。     

Treatment strategy for synchronous metastases of colorectal cancer: is hepatic resection after an observation interval appropriate?

Background In cases of synchronous colorectal hepatic metastases, the primary colorectal cancer strongly influences on the metastases. Our treatment policy has been to conduct hepatic resection for the metastases at an interval of 3 months after colorectal resection. We examined the appropriateness of interval hepatic resection for synchronous hepatic metastasis. Materials and methods The subjects were 164 patients who underwent resection of hepatic metastasis of colorectal cancer (synchronous, 70 patients; metachronous, 94 patients). Background factors for hepatic metastasis and postoperative results were compared for synchronous and metachronous cases. Results The cumulative survival rate for 164 patients at 3, 5, and 10 years postoperatively was 71.9%, 51.8%, and 36.6%, and the post-resection recurrence rate in remnant livers was 26.8%. Interval resection for synchronous hepatic metastases was conducted in 49 cases after a mean interval of 131 days. No difference was seen in postoperative outcome between synchronous and metachronous cases. Conclusion The outcome was similarly favorable in cases of synchronous hepatic metastasis and in cases of metachronous metastasis. Delaying resection allows accurate understanding of the number and location of hepatic metastases, and is beneficial in determining candidates for surgery and in selecting surgical procedure.     

慢性乙型肝炎患者病毒e系统状态与肝纤维化关系的研究

目的:观察慢性乙型肝炎患者乙型肝炎病毒e系统状态和复制指标在肝纤维化发生过程中的变化及其与血清纤维化标志的关系,探讨它们在肝纤维化发生过程中的作用及其可能的临床意义.方法:188例慢性乙型肝炎患者根据肝纤维化程度分为S0～S4期等5组,分别用定量PCR及放免法检测患者血清中HBV-DNA及肝纤维化标志透明质酸、Ⅳ型胶原、Ⅲ型前胶原和层粘连蛋白的含量;HBeAg和抗-HBe采用酶联免疫吸附法(ELISA)检测,并观察其在不同肝病理纤维化分期时的变化.结果:随着肝纤维化程度加重,血清HBV-DNA含量逐渐升高,从S1期开始显著增加(P＜0.01);而HBeAg阳性率逐渐降低,S3、S4期较S0显著减少(P＜0.05和P＜0.01);抗-HBe阳性率呈相反的变化趋势,在S3和S4期的阳性率明显高于S0期(P＜0.05和P＜0.01).血清HBV-DNA( )HBeAg( )组血清纤维化标志最低,HBV-DNA(-)抗-HBe( )组最高,两者差异有显著性(P＜0.01).结论:HBV复制和e系统状态的改变与肝纤维化程度密切相关,肝内病毒复制标志与血清纤维化标志联合检测,对于判断肝纤维化程度和指导抗病毒治疗有重要的价值.     

柔肝消瘢饮对肝硬化大鼠血清和肝组织IL-1β和IL-6含量的影响

目的：观察柔肝消瘕饮对肝硬化大鼠肝组织病理形态学和血清、肝组织IL-1β、IL-6含量的影响。方法：采用复合因素造模法复制肝硬化大鼠模型，以复方鳖甲软肝片为对照，观察柔肝消瘢饮对肝硬化大鼠肝组织病理形态学、血清和肝组织IL-1β、IL-6含量的影响。结果：与正常组比较，模型组大鼠出现肝小叶损害，纤维组织增生，假小叶形成，血清IL-1β、IL-6含量和肝组织IL-6含量均明显升高（P〈0．01或P〈0．05）；与模型组比较，各治疗组肝组织病理损害减轻，血清IL-1β和肝组织IL-6含量均有明显下降，差异有显著性意义（P〈0．01或P〈0．05）；与对照组比较，高剂量组血清IL-6含量明显降低（P〈0．05）。结论：柔肝消瘢饮能显著下调肝硬化大鼠血清IL-1β、IL-6含量和肝组织IL-6含量，具有减轻肝硬化炎症损害，改善肝组织病理形态学作用。